(Source: Business Wire)IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that Donald G. Otterbein has been named general manager, Business Transformation Services, a new role. He reports to David R. Carlucci, IMS chairman and CEO, and will lead the company's growth in commercial analytics outsourcing of pharmaceutical clients' sales, marketing and managed markets activities. IMS is extending its Knowledge Process Outsourcing (KPO) capabilities as clients seek new ways to drive commercial excellence and more meaningful cost efficiencies in today's dynamic healthcare environment.

"At a time when pharmaceutical companies are looking for agility and innovation in their business models, IMS is delivering powerful expertise to help them transform their commercial operations and processes," said Carlucci. "With more than 20 years' experience in developing and deploying innovative offerings for our clients, Don Otterbein has a keen understanding of evolving industry challenges, and what it takes to drive process improvement. He'll ensure that we deliver tailored, high-value solutions to clients as we help accelerate their efforts to improve productivity, reduce costs and add greater flexibility to their operations."

Through IMS Knowledge Process Outsourcing, discrete tasks and end-to-end functions currently handled within clients' commercial organizations are managed by IMS -- applying the company's extensive industry experience with methodologies honed over hundreds of client engagements. KPO projects typically are multi-year in nature, and support three key commercial activities:

Sales Performance Management and Operations, including incentive compensation, call planning, segmentation, CRM and sales administration.

Marketing & Market Research, covering data integration, performance reporting and analysis, data management and forecasting.

Managed Markets Analytics, focusing on contract management and administration, and government pricing and rebates.

For more than 55 years, IMS has been a trusted partner to the pharmaceutical industry -- with information and analytics that offer an unparalleled understanding of market dynamics and, over the past decade, with consulting and services focused on actionable strategies and recommendations.